Marcelo Bigal Acquires 1,512 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) Director Marcelo Bigal bought 1,512 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were purchased at an average price of $13.25 per share, for a total transaction of $20,034.00. Following the completion of the purchase, the director now directly owns 10,142 shares of the company’s stock, valued at approximately $134,381.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX opened at $13.89 on Wednesday. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $38.23. The stock has a market capitalization of $646.52 million, a price-to-earnings ratio of 9.71 and a beta of 0.88. The company has a 50-day simple moving average of $21.68 and a 200-day simple moving average of $26.42. The company has a debt-to-equity ratio of 0.67, a quick ratio of 5.70 and a current ratio of 6.82.

Pacira BioSciences (NASDAQ:PCRX) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.53 by $0.11. Pacira BioSciences had a return on equity of 13.22% and a net margin of 9.21%. The firm had revenue of $178.02 million during the quarter, compared to the consensus estimate of $173.31 million. On average, analysts predict that Pacira BioSciences, Inc. will post 2.22 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on PCRX. StockNews.com lowered shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Monday, August 12th. Barclays cut Pacira BioSciences from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $38.00 to $25.00 in a research note on Wednesday, July 3rd. Needham & Company LLC dropped their target price on shares of Pacira BioSciences from $43.00 to $22.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. JPMorgan Chase & Co. reissued an “underweight” rating and issued a $10.00 price target (down from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. Finally, Raymond James lowered Pacira BioSciences from an “outperform” rating to a “market perform” rating in a report on Monday, August 12th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $24.78.

Institutional Investors Weigh In On Pacira BioSciences

Several large investors have recently modified their holdings of PCRX. ICA Group Wealth Management LLC acquired a new position in Pacira BioSciences in the 4th quarter valued at $30,000. GAMMA Investing LLC boosted its holdings in shares of Pacira BioSciences by 229.6% in the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock valued at $38,000 after acquiring an additional 932 shares in the last quarter. Park Place Capital Corp purchased a new stake in shares of Pacira BioSciences in the second quarter valued at about $46,000. Innealta Capital LLC acquired a new position in shares of Pacira BioSciences during the second quarter worth about $50,000. Finally, nVerses Capital LLC raised its holdings in Pacira BioSciences by 800.0% during the second quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock worth $51,000 after purchasing an additional 1,600 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.